Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212966 | 0.92 | RXFP1 (0.50) | KDM4EALDH1A1HPGDPKMTP53 | |
| SCHEMBL27644686 | 0.90 | KLKB1 (0.54) | KDM4EALDH1A1HPGDPKMTP53 | |
| SCHEMBL5758889 | 0.89 | CNR1 (0.50) | ALDH1A1HPGDTP53POLBELANE | |
| SCHEMBL5757751 | 0.83 | HPGD (0.52) | KDM4EALDH1A1HPGDPKMTP53 | |
| SCHEMBL5758879 | 0.82 | MAPT (0.52) | KDM4EALDH1A1HPGDPKMTP53 | |
| SCHEMBL5759600 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1HPGDPKMTP53 | |
| SCHEMBL5756649 | 0.82 | KMT2A (0.46) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL5757366 | 0.82 | ELANE (0.58) | KDM4EALDH1A1HPGDPKMTP53 | |
| SCHEMBL27644966 | 0.81 | HPGD (0.50) | KDM4EALDH1A1HPGDPKMTP53 | |
| SCHEMBL6213682 | 0.80 | MAPT (0.54) | KDM4EALDH1A1HPGDPKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | KDM4E 3110/4885ALDH1A1 1465/4885HPGD 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.